Journal article
The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life
A Dunn Galvin, S McMahon, AL Ponsonby, KC Hsiao, MLK Tang, W Burks, S Donath, F Orsini, D Tey, M Robinson, EL Su, C Axelrad
Allergy European Journal of Allergy and Clinical Immunology | WILEY | Published : 2018
DOI: 10.1111/all.13330
Abstract
Background: We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double-blind, placebo-controlled randomized trial. This study evaluated the impact of PPOIT on health-related quality of life (HRQL). Method: Fifty-one participants (PPOIT 24; placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ-PF) and Food Allergy Independent Measure (FAIM) at pre-treatment, end-of-treatment and 3 months after end-of-treatment. A total of 42 participants (20 PPOIT; 22 placebo) completed measures at 12 months post-treatment. Changes over time in PPOIT and placebo groups..
View full abstractGrants
Awarded by Food Allergy and Anaphylaxis Network
Funding Acknowledgements
The parent study was supported by the Food Allergy and Anaphylaxis Network (FAAN), the Murdoch Childrens Research Institute, Perpetual Philanthropy (grant ID 493), the CASS Foundation, the Financial Markets Foundation for Children and the National Health and Medical Research Council Australia (NHMRC project grant no. 1029690). This current study examining the predetermined secondary outcomes of HRQL was not funded.